Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 8/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398428 | 0.94 | PDE4D (0.40) | CNR1PDE4DTOP2ATNFCREBBP | |
| SCHEMBL12809066 | 0.81 | CNR1 (0.42) | CNR1TOP2ATNFCREBBPLMNA | |
| SCHEMBL13332362 | 0.81 | CNR1 (0.42) | CNR1TOP2ATNFCREBBPLMNA | |
| SCHEMBL1398457 | 0.78 | TNF (0.47) | CNR1PDE4DTOP2ATNFLMNA | |
| SCHEMBL1398590 | 0.77 | S1PR1 (0.43) | CNR1PDE4DTOP2ATNF | |
| SCHEMBL1398484 | 0.77 | CNR1 (0.47) | CNR1PDE4DTOP2ATNFCNR2 | |
| SCHEMBL402819 | 0.77 | CNR1 (0.59) | CNR1TNFCNR2CREBBPLMNA | |
| SCHEMBL13584130 | 0.76 | TNF (0.46) | CNR1PDE4DTOP2ATNFLMNA | |
| SCHEMBL12808842 | 0.74 | CREBBP (0.40) | CNR1PDE4DTOP2ACREBBPLMNA | |
| SCHEMBL1398527 | 0.72 | CREBBP (0.42) | CNR1TNFCREBBPLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2137181-B1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LTD (GB) | 2011-03-02 | — | — | EP | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| EP-2137181-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | S1PR1, S1PR3, S1PR2 | CNR1 31/4885PDE4D 371/4885TOP2A 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.